Patents Assigned to Allelix Biopharmaceuticals Inc.
  • Patent number: 5602121
    Abstract: Described herein are D4 receptor-selective compounds of the general formula: ##STR1## wherein: A and B are independently selected, optionally substituted, saturated or unsaturated 5- or 6-membered, homo- or heterocyclic rings;X.sub.1 is selected from CH.sub.2, O, NH, S, C.dbd.O, CH--OH, CH--N(C.sub.1-4 alkyl).sub.2, C.dbd.CHCl, C.dbd.CHCN, N--C.sub.1-4 alkyl, N-acetyl, SO.sub.2 and SO;X.sub.2 . . . is selected from N.dbd., CH.sub.2 --, CH.dbd., C(O)--, O--, and S--;Y is selected from N and CH;R.sub.1 represents C.sub.1-4 alkyl;n is 0, 1 or 2;q is 1 or 2; andZ is C.sub.5-10 alkyl optionally substituted with OH, halo, C.sub.1-4 alkyl or C.sub.1-4 alkoxy and optionally incorporating a heteroatom selected from O, N and S;and acid addition salts, solvates and hydrates thereof. Their use as ligands for dopamine receptor identification and in a drug screening program, and as pharmaceuticals to treat indications in which the D4 receptor is implicated, such as schizophrenia, is also described.
    Type: Grant
    Filed: December 12, 1994
    Date of Patent: February 11, 1997
    Assignee: Allelix Biopharmaceuticals, Inc.
    Inventor: Jian-Min Fu
  • Patent number: 5602124
    Abstract: Described herein are 5-HT2 receptor-selective compounds of Formula I: ##STR1## wherein: A and B are independently selected, optionally substituted, saturated or unsaturated 5- or 6-membered, homo- or heterocyclic rings;X.sub.1 is selected from CH.sub.2, O, NH, S, C.dbd.O, CH--OH, CH--N(C.sub.1-4 alkyl).sub.2, C.dbd.CHCl, C.dbd.CHCN, N--C.sub.1-4 alkyl, N-acetyl, SO.sub.2 and SO;X.sub.2 - - - is selected from N.dbd., CH.sub.2 --, CH.dbd., C(O)--, O--, and S--;R.sub.1 is C.sub.1-6 alkyl optionally substituted with a substituent selected from OH, halo, C.sub.1-4 alkyl and C.sub.1-4 alkoxy; andR.sub.2, R.sub.3 and R.sub.4 are independently selected from H and R.sub.1 ;and acid addition salts, solvates and hydrates thereof.
    Type: Grant
    Filed: December 12, 1994
    Date of Patent: February 11, 1997
    Assignee: Allelix Biopharmaceuticals, Inc.
    Inventors: Ashok Tehim, Jian-Min Fu, Sumanas Rakhit
  • Patent number: 5599792
    Abstract: Described herein are Met.sup.8 -substituted variants of parathyroid hormone that retain bone stimulating activity yet, unlike their native counterparts, have substantially no vasoactivity. Their production using recombinant DNA-based techniques is also described, as is their therapeutic use, e.g. in the treatment of osteoporosis.
    Type: Grant
    Filed: October 31, 1994
    Date of Patent: February 4, 1997
    Assignee: Allelix Biopharmaceuticals Inc.
    Inventors: K. Anne Kronis, Richard P. Bozzato
  • Patent number: 5595969
    Abstract: A novel steroid-binding variant of human corticosteroid binding globulin in which one or more of the glycosylation sites, other than the glycosylation site at amino acid position 238, has been functionally disrupted is complexed with an anti-inflammatory ligand in the treatment of inflammation in mammals.
    Type: Grant
    Filed: April 14, 1995
    Date of Patent: January 21, 1997
    Assignee: Allelix Biopharmaceutical Inc.
    Inventors: Geoffrey L. Hammond, George V. Avvakumov
  • Patent number: 5576205
    Abstract: Neurotransmission by excitatory amino acids (EAAs) such as glutamate is mediated via membrane-bound surface receptors. DNA coding for one family of these receptors, of the kainate binding type of EAA receptors, has now been isolated and the receptor protein characterized. Herein described are recombinant cell lines which produce the EAA receptor as a heterologous membrane-bound product. Also described are related aspects of the invention, which are of commercial significance. Included is use of the cell lines as a tool for discovery of compounds which modulate EAA receptor stimulation.
    Type: Grant
    Filed: January 24, 1994
    Date of Patent: November 19, 1996
    Assignee: Allelix Biopharmaceuticals, Inc.
    Inventors: Rajender Kamboj, Stephen L. Nutt, Lee Shekter, Michael A. Wosnick
  • Patent number: 5576314
    Abstract: Described herein are D4 receptor-selective compounds of the general formula: ##STR1## wherein: A and B are independently selected, optionally substituted, saturated or unsaturated 5- or 6-membered, homo- or heterocyclic rings;X.sub.1 is selected from CH.sub.2, O, NH, S, C.dbd.O, CH--OH, CH--N(C.sub.1-4 alkyl).sub.2, C.dbd.CHCl, C.dbd.CHCN, N-C.sub.1-4 alkyl, N-acetyl, SO.sub.2 and SO;X.sub.2 - - - is selected from N.dbd., CH.sub.2 --, CH.dbd., C(O)--, O--, and S--;n is 1 or 2;R.sub.1 is selected from H and an amino acid side chain;R.sub.2 is selected from H, OH, C.sub.1-9 alkyl, C.sub.1-9 alkoxy, and benzyloxy; andR.sub.3 is selected from H, OH, halo, cyano, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, phenoxy, benzyloxy, .dbd.O, .dbd.S, C.sub.1-4 alkylsulfonyl, C.sub.1-4 alkylsulfonyl, C.sub.1-4 alkylthio, amino, and aminocarbonyl;and acid addition salts, solvates and hydrates thereof.
    Type: Grant
    Filed: December 12, 1994
    Date of Patent: November 19, 1996
    Assignee: Allelix Biopharmaceuticals Inc.
    Inventors: Patricia L. Power, Sumanas Rakhit
  • Patent number: 5574144
    Abstract: Neurotransmission by excitatory amino acids (EAAs) such as glutamate is mediated via membrane-bound surface receptors. DNA coding for one family of these receptors of the kainate-binding type of EAA receptors, has now been isolated and the receptor protein characterized. Herein described are recombinant cell lines which produce the EAA receptor as a heterologous membrane-bound product. Also described are related aspects of the invention, which are of commercial significance. Included is use of the cell lines as a tool for discovery of compounds which modulate EAA receptor stimulation.
    Type: Grant
    Filed: June 24, 1992
    Date of Patent: November 12, 1996
    Assignee: Allelix Biopharmaceuticals, Inc.
    Inventors: Rajender Kamboj, Candace E. Elliott, Stephen L. Nutt
  • Patent number: 5561127
    Abstract: Described herein are D4 receptor-selective compounds of the general formula I: ##STR1## wherein: A and B are independently selected, optionally substituted, saturated or unsaturated 5- or 6-membered, homo- or heterocyclic rings;X.sub.1 is selected from CH.sub.2, O, NH, S, C.dbd.O, CH--OH, CH--NEt.sub.2, C.dbd.CHCl, C.dbd.CHCN, N--C.sub.1-4 alkyl, N-acetyl, SO.sub.2 and SO;X.sub.2 --is selected from N.dbd., CH.sub.2 --, CH.dbd., C(O)--, O--, and S--;n is 1 or 2; andZ is selected from C.sub.1-6 alkyl optionally substituted with a substituent selected from OH, halo, C.sub.1-4 alkyl and C.sub.1-4 alkoxy;and acid addition salts, solvates and hydrates thereof. Their use as ligands for dopamine receptor identification and in a drug screening program, and as pharmaceuticals to treat indications in which the M1/M2 receptor is implicated, such as schizophrenia, is also described.
    Type: Grant
    Filed: December 19, 1994
    Date of Patent: October 1, 1996
    Assignee: Allelix Biopharmaceuticals, Inc.
    Inventors: Ashok Tehim, Sumanas Rakhit
  • Patent number: 5547855
    Abstract: Neurotransmission by excitatory amino acids (EAAs) such as glutamate is mediated via membrane-bound surface receptors. DNA coding for one family of the kainate-binding type of EAA receptor, has now been isolated and the receptor protein characterized. Herein described are recombinant cell lines which produce the EAA receptor as a heterologous membrane-bound product. Disclosed is use of the cell lines as a tool for discovery of compounds which modulate EAA receptor stimulation.
    Type: Grant
    Filed: March 15, 1995
    Date of Patent: August 20, 1996
    Assignee: Allelix Biopharmaceuticals Inc.
    Inventors: Rajender Kamboj, Candace E. Elliott, Stephen L. Nutt
  • Patent number: 5538965
    Abstract: Described herein are D4 receptor-selective compounds of the general formula: ##STR1## wherein: A and B are independently selected, optionally substituted, saturated or unsaturated 5- or 6-membered, homo- or heterocyclic rings;X.sub.1 is selected from CH.sub.2, O, NH, S, C.dbd.O, CH--OH, CH--N(C.sub.1-4 alkyl).sub.2, C.dbd.CHCl, C.dbd.CHCN, N-C.sub.1-4 alkyl, N-acetyl, SO.sub.2 and SO;X.sub.2 -- is selected from N.dbd., CH.sub.2 --, CH.dbd., C(O)--, O--, and S--;R.sub.1 represents C.sub.1-4 alkyl;Y is selected from CH and N;n is 0, 1 or 2;q is 1 or 2;R.sub.2 is C.sub.1-6 alkyl optionally incorporating a heteroatom selected from N, O and S;D is cyclohexane or benzene; andE is a saturated or unsaturated 5- or 6-membered heterocycle incorporating 1, 2 or 3 heteroatoms selected from O, N, and S, wherein E is optionally substituted with 1 or 2 substituents selected from halogen, C.sub.1-4 alkyl and halogen-substituted C.sub.1-4 alkyl;and acid addition salts, solvates and hydrates thereof.
    Type: Grant
    Filed: December 12, 1994
    Date of Patent: July 23, 1996
    Assignee: Allelix Biopharmaceuticals Inc.
    Inventors: Ashok Tehim, Jian-Min Fu, Sumanas Rakhit
  • Patent number: 5504101
    Abstract: Described herein are tryptamine analogs that display high binding affinity and selectivity for the 5-HT1D.beta. receptor, of the formula: ##STR1## wherein R.sup.1 is a group selected from aryl-C.sub.1-7 alkyl; aryl-C.sub.2-7 alkoxy; aryl-C.sub.2-7 alkanoyl and aryl-C.sub.1-7 alkanoyloxy, wherein said alkyl, alkoxy, alkanoyl and alkanoyloxy groups are optionally substituted by a C.sub.1-4 alkyl substituent and wherein said aryl group is optionally substituted by one or more substituent selected from hydroxyl, halogen, mercapto, linear or branched C.sub.1-4 alkyl, linear or branched C.sub.1-4 alkoxy, linear or branched C.sub.1-4 alkylthio, thiol substituted C.sub.1-4 alkyl and nitro substituted C.sub.1-4 alkyl;R.sup.2 and R.sup.3 are selected independently from H and C.sub.1-4 alkyl; andR.sup.4 is selected from H, C.sub.1-4 alkyl, aryl and arylC.sub.1-4 alkyl.
    Type: Grant
    Filed: May 6, 1994
    Date of Patent: April 2, 1996
    Assignee: Allelix Biopharmaceuticals, Inc.
    Inventor: Richard A. Glennon
  • Patent number: 5496801
    Abstract: Described herein are preparations containing parathyroid hormone that has been stablized with an excipient and buffering agent. Preferred preparations incorporate human PTH(1-84), mannitol as excipient and citrate as buffering agent, and are incorporated in vials as a freeze-dried powder for reconstitution to treat osteoporosis.
    Type: Grant
    Filed: December 23, 1993
    Date of Patent: March 5, 1996
    Assignee: Allelix BioPharmaceuticals Inc.
    Inventors: Josephus J. M. Holthuis, Albert Mekking, Alwinus A. Voetman
  • Patent number: 5495006
    Abstract: The herpes simplex virus encodes ICP4, a DNA binding protein. ICP4-binding duplexed structures having significantly enhanced stability under physiological conditions are described. The structures are provided in the form of polynucleotide conjugates capable of adopting a duplexed structure, in which annealable polynucleotide strands are coupled covalently at one or both ends through a chemical linker which establishes a stabilizing bridge between strands. The present polynucleotide conjugates have therapeutic utility against viral infection as the polynucleotide strands thereof define a binding site for a viral regulatory protein, thereby inactivating the protein and preventing viral replication from occurring.
    Type: Grant
    Filed: March 1, 1993
    Date of Patent: February 27, 1996
    Assignee: Allelix Biopharmaceuticals, Inc.
    Inventors: Shane Climie, Michael Ma
  • Patent number: 5494792
    Abstract: Neurotransmission by excitatory amino acids (EAAs) such as glutamate is mediated via membrane-bound surface receptors. DNA coding for one family of these receptors, of the kainate binding type of EAA receptors, has now been isolated and the receptor protein characterized. Herein described are recombinant cell lines which produce the EAA receptor as a heterologous membrane-bound product. Also described are related aspects of the invention, which are of commerical significance. Included is use of the cell lines as a tool for discovery of compounds which modulate EAA receptor stimulation.
    Type: Grant
    Filed: July 15, 1993
    Date of Patent: February 27, 1996
    Assignee: Allelix Biopharmaceuticals Inc.
    Inventors: Rajender Kamboj, Stephen L. Nutt, Lee Shekter, Michael A. Wosnick
  • Patent number: 5432080
    Abstract: A novel steroid-binding variant of human corticosteroid binding globulin in which one or more of the glycosylation sites, other than the glycosylation site at amino acid position 238, has been functionally disrupted is complexed with an anti-inflammatory ligand in the treatment of inflammation in mammals.
    Type: Grant
    Filed: December 16, 1992
    Date of Patent: July 11, 1995
    Assignee: Allelix Biopharmaceuticals Inc.
    Inventors: Geoffrey L. Hammond, George V. Avvakumov
  • Patent number: 5403825
    Abstract: Described is a purified osteogenic factor that when delivered to bone in association with a physiologically acceptable delivery vehicle is capable of inducing new bone growth at the bone surface. The osteogenic factor is water soluble, and is characterized physically by a molecular weight of about 2.5 kD when measured by gel filtration under dissociating conditions and an isoelectric point in the pH range from about 4.6 to 7.2. Use of the purified factor in treating bone defects is described. Also described is a method for obtaining the purified factor from mammalian bone.
    Type: Grant
    Filed: September 1, 1992
    Date of Patent: April 4, 1995
    Assignee: Allelix Biopharmaceuticals Inc.
    Inventors: Alain E. Lagarde, Abdulwahid Abdulwajid, Donna Bueschkens, Deanna Byrne
  • Patent number: 5382658
    Abstract: Herein described are variants of parathyroid hormone that retain significant PTH activity and are substantially resistant to trypsin and trypsin-like enzymes. The variants are useful pharmaceutically, to treat bone disorders such as osteoporosis and in other therapeutic applications. Specific embodiments of the invention include [His.sup.25 ]PTH and [His.sup.25 His.sup.26 Leu.sup.27 ]PTH.
    Type: Grant
    Filed: April 3, 1992
    Date of Patent: January 17, 1995
    Assignees: Allelix Biopharmaceuticals Inc., Glaxo Canada Inc.
    Inventors: K. Anne Kronis, Richard P. Bozzato
  • Patent number: 5344819
    Abstract: Inflammation in mammals is treated by administering anti-inflammatory agent complexed with corticosteroid binding globulin (CBG) that is produced by recombinant DNA-based techniques.
    Type: Grant
    Filed: February 3, 1992
    Date of Patent: September 6, 1994
    Assignee: Allelix Biopharmaceuticals Inc.
    Inventor: Geoffrey L. Hammond
  • Patent number: 5338834
    Abstract: Essentially pure human interleukin-6 having a purity of at least 98 % as determined by single peak migration using capillary electrophoresis is obtained by a 3-step purification method which includes a cation-exchange chromatography step, a hydrophobic chromatography step and a reverse-phase chromatography step in the presence of a charge modifier.
    Type: Grant
    Filed: January 26, 1993
    Date of Patent: August 16, 1994
    Assignee: Allelix Biopharmaceuticals Inc.
    Inventor: Ashley M. Williams
  • Patent number: 5326690
    Abstract: Herein described is an ovarian cancer activating factor that has been isolated from ovarian cancer ascites fluid. The factor may be utilized in its isolated form in a screening program aimed at identifying inhibitors of factor-mediated ovarian cancer activation, or as a growth supplement useful for culturing ovarian and other cancer cell lines.
    Type: Grant
    Filed: October 1, 1993
    Date of Patent: July 5, 1994
    Assignee: Allelix Biopharmaceuticals Inc.
    Inventors: Yan Xu, Anne E. Goodbody